Doing it All - How Families are Reshaping Rare Disease Research

Pharm Res. 2018 Aug 16;35(10):192. doi: 10.1007/s11095-018-2481-7.

Abstract

The face of rare disease drug discovery and development is changing right before our eyes. The outliers of the past were the plucky parents who summoned up the courage to try to treat their children against all odds. Think of the rare disease focused movies 'Lorenzo's Oil' and 'Extraordinary Measures' but now accelerated to develop treatments even quicker. Parents, patient advocates and their collaborators are now capable of doing it all themselves. We think this will have profound implications for everyone from the incumbent rare disease foundations that have held sway for decades to the multibillion dollar rare disease market, BioPharma companies, VCs and angel investors that inhabit this space. The repercussions of this disruption will no doubt impact healthcare in general and ultimately influence how we develop treatments for major diseases as well. We present several lines of evidence for our viewpoint from our personal experiences interacting with many rare disease families and patient advocates in recent years.

Keywords: disruption; drug discovery; machine learning; multiple sulfatase deficiency; rare diseases.

MeSH terms

  • Drug Discovery
  • Foundations
  • Humans
  • Machine Learning
  • Parents
  • Rare Diseases / diagnosis*
  • Rare Diseases / drug therapy*